Advertisement
UK markets close in 8 hours
  • FTSE 100

    8,066.31
    +21.50 (+0.27%)
     
  • FTSE 250

    19,769.79
    -29.93 (-0.15%)
     
  • AIM

    755.51
    +0.64 (+0.08%)
     
  • GBP/EUR

    1.1627
    -0.0001 (-0.01%)
     
  • GBP/USD

    1.2433
    -0.0019 (-0.15%)
     
  • Bitcoin GBP

    53,770.23
    +398.41 (+0.75%)
     
  • CMC Crypto 200

    1,418.32
    -5.78 (-0.41%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    83.36
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,336.30
    -5.80 (-0.25%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,179.29
    +350.36 (+2.08%)
     
  • DAX

    18,172.75
    +35.10 (+0.19%)
     
  • CAC 40

    8,085.74
    -20.04 (-0.25%)
     

Tamiflu (Oseltamivir Phosphate) Market Report 2021-2031: Visiongain Research Inc.

Visiongain has published a new report on Tamiflu (Oseltamivir Phosphate) Market Report 2021 to 2031: Forecasts By Drug Type (Branded Drug, and Generic Drug), By Dosage Form (Capsule, and Suspension), By Indication (Influenza A, Influenza B, and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By End User (Hospital, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

COVID-19 Impact on Tamiflu (Oseltamivir Phosphate)

COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Tamiflu (Oseltamivir Phosphate). Different recovery scenarios are also included in the report for all the segments and regions/nations. The recovery scenarios based on which market has been forecasted and analyzed herein the report are mentioned below:

Download Exclusive Sample of Report @ https://www.visiongain.com/report/tamiflu-market-2021/#download_sampe_div

ADVERTISEMENT

Market Drivers

Increasing Prevalence of Influenza and Flu
Influenza and flu prevalence has increased very rapidly as compared to the last few years and it is expected that Influenza and flu prevalence will increase during the forecast period. According to the U.S. Department of Health & Human Services that approximately 35.5 million are suffering from influenza. Increasing influenza and flu cases creates a huge demand for the influenza and flu treatment. Due to which increasing prevalence of influenza and flu is working as a driver for the Influenza and flu treatment market.

Rising Investment in Tamiflu (Oseltamivir Phosphate)
There is a very rapid increase in demand of tamiflu (Oseltamivir Phosphate) around the world for the Influenza and flu. Recently, the market has reported a sudden rise in the demand of Tamiflu (Oseltamivir Phosphate) along with increasing regulatory approvals, new investment and growing initiatives. Various manufactures have increased their funding for tamiflu (Oseltamivir Phosphate) and on the other hand many manufacturers have launched their product portfolios in tamiflu (Oseltamivir Phosphate) which have helped to fulfil demand and to work as driver for the market. Rapid surge in the investment is increasing demand of tamiflu (Oseltamivir Phosphate) products due to this reason the factor is working as a driver for the market.

Market Opportunities

Increasing Strategic Initiatives In Retinal Disorders Treatment Drugs
Manufactures present in the market are taking various strategic initiatives in order to increase their revenue generation in the market, Strategic Initiatives such as mergers & acquisitions, product launches and press conference & event. These strategic initiatives are helping manufacturers in the market to increase their revenue generation due to this reason increasing strategic initiatives in tamiflu (Oseltamivir Phosphate) market is creating new opportunities for the Tamiflu (Oseltamivir Phosphate) market.

Get Detailed TOC @ https://www.visiongain.com/report/tamiflu-market-2021/#download_sampe_div

How the Tamiflu (Oseltamivir Phosphate) Market report helps you
In summary, our 300+ page report provides you with the following knowledge:

  • Revenue forecasts to 2031 for Tamiflu (Oseltamivir Phosphate) Market, with forecasts for Get our report today Tamiflu (Oseltamivir Phosphate) Market Forecast 2021-2031: By Drug Type, Dosage Form, Indication, Patient Demographics, By End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

  • Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Tamiflu (Oseltamivir Phosphate) market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.

  • Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Tamiflu Market.

Competitive Landscape

Top companies (F.Hoffmann-La Roche Ltd., NATCO Pharma Limited, and Teva Pharmaceutical Industries Ltd..) own the lion share of the global Tamiflu (Oseltamivir Phosphate). Other companies profiled in the report include LUPIN Limited, Amneal pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Mylan N.V., Hetero GroupSome of the key developments are listed below:

In 2019, Alembic Pharmaceuticals received the U.S. Food and Drug Administration approval for Oseltamivir phosphate capsules. Oseltamivir phosphate is a generic version of Tamiflu and is designed for the treatment of acute, uncomplicated illness due to influenza A and B infection. The approval will help the company to expand its market portfolio.

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With our report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Oseltamivir Phosphate Market and leading companies. You will find data, trends, and predictions.

Find more Visiongain research reports on Therapeutic Drugs Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.